Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells

(1) Background: TP53 deficiency remains a major adverse event in Multiple Myeloma (MM) despite therapeutic progresses. As it is not possible to target TP53 deficiency with pharmacological agents, we explored the possibility of activating another p53 family member, p73, which has not been well studie...

Descripción completa

Detalles Bibliográficos
Autores principales: Gillardin, Pierre-Samuel, Descamps, Géraldine, Maiga, Sophie, Tessoulin, Benoit, Djamai, Hanane, Lucani, Benedetta, Chiron, David, Moreau, Philippe, Le Gouill, Steven, Amiot, Martine, Pellat-Deceunynck, Catherine, Moreau-Aubry, Agnès
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795990/
https://www.ncbi.nlm.nih.gov/pubmed/29295500
http://dx.doi.org/10.3390/ijms19010040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795990/
https://www.ncbi.nlm.nih.gov/pubmed/29295500
http://dx.doi.org/10.3390/ijms19010040

Ejemplares similares